PEG-IFN for Chronic Hepatitis B Treatment
Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens
Recruiting
N/A
Interventional Study
Hepatitis B, Chronic
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 72 (estimated)
- Sponsor
- Huashan Hospital · Other
Who this trial is looking for
This trial is looking for adults with chronic hepatitis B who have been treated with specific therapies before. Participants will receive a new treatment with PEG-IFN for 24 weeks, with follow-up monitoring to see how well it works.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have chronic hepatitis B infection.
- I have taken part in prior therapies for hepatitis B.
- I have seen a significant decrease in HBsAg levels from my previous therapy.
- I stopped my previous hepatitis treatment before this trial.
- My HBsAg level is between 1-500 IU/mL.
- I have not had interferon therapy in the last 6 months.
- I agree to use contraception during the study.
You may not be able to join if
- I have advanced liver disease or liver cancer.
- I have high AFP levels or liver cancer.
- I am infected with other types of hepatitis viruses or HIV.
- I have taken certain immune therapies within the last 6 months.
- I am pregnant, breastfeeding, or planning to become pregnant.
- I have autoimmune hepatitis or other serious autoimmune diseases.
- I have uncontrolled heart disease or other significant health issues.
- I have a history of severe mental health disorders.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to compare sequential PEG-IFNα therapy strategies in chronic hepatitis B (CHB) patients previously treated with ASO/siRNA. The main questions it aims to answer are:
1. Does sequential PEG-IFNα therapy (vs. deferred/no treatment) improve HBsAg clearance rates?
2. What are the HBsAg clearance and relapse rates after 24 weeks of PEG-IFNα therapy?
3. Is intermittent…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years.
* Chronic HBV infection (documented HBsAg positivity for \>6 months).
* Prior participation in ASO or siRNA clinical trials:
* Received ≥1 dose of ASO/siRNA (or matched placebo, if applicable).
* Achieved ≥1 log10 IU/mL HBsAg decline from baseline during prior t…
Contacts